Pioneering high-yield cell suspension line
Long before many AAV manufacturers existed, we recognized a universal need that crosses all AAV therapeutics – the need for a process that increases production and lowers manufacturing cost. In 2010, we introduced Pro10™, a cell line for generating novel AAV therapeutics. Our system uses a human embryonic kidney (HEK)-based cell line in serum-free suspension media to develop and produce AAV vectors.
Pro10™ was one of the first HEK293 based suspension cell line to achieve high-yield AAV manufacturing without using any human or animal derived by-products to grow in bioreactors. This results in highly efficient and scalable AAV vector manufacturing.
Pro10™ is used in AskBio’s Viralgen manufacturing facilities and is licensed by leading global biopharma companies.
- Produces high yields of AAV vectors
- Universal manufacturing system that produces several serotypes and chimeric capsids packaging single-stranded and self-complementary genomes
- Cost advantages with transient transfection of a patent-protected cell line
- Scalable production from benchtop to bioreactor allowing for early assessment of vectors enabling rapid scale-up
Clinical and commercial GMP manufacturing
Our extensive manufacturing facilities in San Sebastian, Spain, allow for high-yield output of AAV vectors and for the production of neDNA™, a benchtop alternative to plasmid DNA.
Advancing capsid development
Our capability to design novel capsids with tissue/cell selectivity, immune system evasion, minimal off-target risk and defined transduction attributes advances conventional capsid design processes.
